Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Phase 2 Terminated 12 enrolled Nasser Hanna, M.D. Hoosier Cancer Research Network · collab Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, multi-institutional, single arm phase II trial of pembrolizumab in patients with incurable platinum refractory germ cell tumors. No randomization or blinding is involved.

Timeline

Start: 2016-01
Primary completion: 2017-01-13
Completion: 2017-01-13

Outcome

Outcome not reported

Stopped: “Lack of Efficacy”

Publications

Adra N, Einhorn LH, Althouse SK, Ammakkanavar NR, Musapatika D, Albany C, Vaughn D, Hanna NH. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol. 2018 Jan 1;29(1):209-214. doi: 10.1093/annonc/mdx680.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous